Point of delivery cold slurry generation

Abstract
The present invention provides methods and devices for making a cold slurry at a point of delivery. A point of delivery device delivers cold slurry components to a location at or near a target tissue. The components are combined to form the cold slurry at or near the point of delivery. This approach to generating a cold slurry at the point of delivery allows the characteristics of the cold slurry, such as temperature, particle shape and particle size, to be maintained and controlled.
Description
BACKGROUND

Cold slurries used in medical applications typically comprise a partially frozen saline solution. Cold slurries are used in surgical applications to induce therapeutic hypothermia and slow organ and tissue metabolic rates thereby protecting a patient's organs during a surgical procedure. Cold slurries can also be injected into a patient for selective or non-selective cryotherapy and/or cryolipolysis.


Approaches to preparing and delivering a cold slurry to fat tissue through a cannula or needle are reported in International Application No. PCT/US2015/047292; U.S. patent application Publication No. 2013/0190744; and U.S. Provisional Application No. 62/416484, which are incorporated by reference herein in their entirety. An injectable cold slurry typically can have particle sizes ranging from 0.1 millimeters to 1.5 millimeters. The particles are generally globular in shape giving the cold slurry high fluidity. This allows the slurry to flow easily through a small diameter needle. In contrast, an ice slush consisting of dendritic crystals is difficult to inject without clogging.


A traditional approach to making an injectable cold slurry is to mix a saline solution with ice, crush it, and condition it prior to injection. The resulting cold slurry is then transferred to a syringe for injection. There are many challenges with this approach, including maintaining temperature, shape, and size of the cold slurry particles. As the slurry warms, the particles lose the desired shape and size. The problem of melting cold slurry is further exacerbated when a large amount of cold slurry needs to be delivered to many different areas. By the time the last injection of cold slurry is made, the cold slurry is markedly different than when first injected. Refreezing the cold slurry is not an option because doing so causes dendritic crystals to form that may clog the syringe needle.


SUMMARY

The present invention provides methods and devices for making a cold slurry at a point of delivery. A point of delivery device delivers cold slurry components to a location at or near a target tissue. The components are combined to form the cold slurry at or near the point of delivery. This approach to generating a cold slurry at the point-of-delivery allows the characteristics of the cold slurry, such as temperature, particle shape and particle size, to be maintained and controlled


Point of delivery generation also allows cold slurry to be made on demand and on a continuous basis. This is particularly useful for treatment over an extended period of time during which melting can occur. The point of care, just-in-time slurry delivery of the invention delivers fresh cold slurry over an entire course of treatment obviating concerns over melting and slurry decomposition. The invention can also greatly reduce the cost and time associated with making cold slurry in batches.


One aspect of the invention comprises methods of making a cold slurry at or near a target tissue. Preferred methods include delivering components needed to make a cold slurry.


A first component can be water or a water mixture, such as water and glycerol. Cold slurry is formed at or near the target tissue as a result of interaction between the components. The delivery of components for making a cold slurry; and the formation of a cold slurry can occur continuously so that there is steady supply of fresh cold slurry at or near the target tissue.


Preferred ingredients for forming a cold slurry include liquid water and solid water. A surfactant, such as glycerol, can be added as well to enhance the fluidity of the cold slurry. Liquid water and the solid water are mixed to form a cold slurry at or near the target tissue. The solid water can be broken into particles that are mixed with the liquid water to form the slurry. Solid water (i.e., ice) can also be formed from another supply of liquid water that is subsequently frozen within the device.


The cold slurry can also be made at or near the target tissue from the nucleation of supercooled water with ice pellets (seeds). In this case the supercooled water is purified liquid water that has been “undercooled” below the freezing point of water. The supercooled water remains in liquid form due, in part, to its purity. When the supercooled water interacts with the ice pellets, it crystallizes and forms the cold slurry.


Methods of the invention are carried out using a point of delivery generation device. An exemplary device includes a first cannula for delivering a first component and a second cannula for delivering a second component to a target tissue. The first and second cannulas can be arranged side-by-side such that their respective outlets are more or less aligned to facilitate cold slurry formation. In some examples, the first and second cannulas each have a size and shape suitable for inserting through the subject's skin.


Cold slurry can also be made at or near a target tissue using a balloon. In a preferred embodiment, the balloon comprises an outer balloon and an inner balloon. The inner balloon is filled with liquid water supplied through, for example, a first delivery cannula. A space between the inner balloon and the outer balloon is filled with a cooling fluid or gas supplied through a second delivery cannula. This causes a cold slurry to form inside the inner balloon. The inner balloon can optionally be punctured (e.g., by a puncturing needle on the device) to release the cold slurry at or near the target tissue. In this example of the point of delivery generation device, the first delivery cannula and the second delivery cannula are arranged coaxially. The invention may also include a temperature sensor to measure the temperature of the cold slurry made at or near the target tissue. Other factors and aspects of the invention are provided in the following detailed description thereof.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 is a diagram of an approach to generating a cold slurry inside a patient's body.



FIG. 2 is a view of a generating end of a point of delivery generation device for forming a cold slurry from liquid water and solid water.



FIG. 3A is a view of a generating end of another point of delivery generation device for forming a cold slurry from liquid water and solid water.



FIG. 3B is a sectional view of the generating end of FIG. 3A.



FIG. 4 is a view of a generating end of a point of delivery generation device for forming solid water from a first supply of liquid water and then forming a cold slurry from the solid water and a second supply of liquid water and .



FIG. 5 is a view of a generating end of a point of delivery generation device for forming a cold slurry from supercooled water and ice pellets.



FIGS. 6A and 6B are views of a generating end of a point of delivery generation device for forming a cold slurry inside a balloon.



FIG. 7 is a view of a point of delivery generation device for generating and replenishing cold slurry.



FIG. 8 is a view of a point of delivery generation device having multiple working channels.





DETAILED DESCRIPTION

Methods and devices of the invention comprise elements for point-of-care delivery of cold slurry to a tissue or organ. The invention obviates the need to pre-mix slurry prior to delivery, thus ensuring that fresh slurry (i.e., uncrystallized and at appropriate phase and temperature) is delivered for the duration of treatment and uniformly to all treatment areas. In a preferred embodiment, slurry is made in situ at a point of delivery in a patient. Components (reactants) used to generate the slurry are provided under conditions that result in the formation of a slurry at an appropriate temperature and of an appropriate consistency for a desired treatment protocol. In a highly-preferred embodiment, methods of the invention are provided subcutaneously to adipose tissue in order to cause reduction of the adipose tissue. Methods and devices of the invention can also be applied to cause reduction of visceral fat, or to reduce pain.



FIG. 1 shows an example of a point of delivery generation device 100 for making a cold slurry inside a patient's body. The device 100 includes an application cannula 105 having a shape and size configured to be inserted through a patient's skin. The device 100 is fluidly coupled to a supply 110 providing components for making a cold slurry. At the distal of the application cannula 105, there is a generating end 115 for forming a cold slurry from the components.


The point of delivery generation device 100 is used by inserting the application cannula 105 through the patient's skin and advancing the generating end 115 to a location at or near a target tissue or treatment site 120 (shown in phantom line). The target tissue 120 can, for example be subcutaneous adipose tissue. The cold slurry ingredients, such as liquid water, solid water, and glycerol, are pumped or otherwise conveyed, separately, from the supply 110, through the application cannula 105, and out the generating end 115. At the generating end 115, the components interact with each other and form the cold slurry 125 at or near the target tissue 120.


The cooling effect of the cold slurry 125 is localized to the target tissue 120 and possibly surrounding tissue, such as adjacent tissue 130. In this way, discomfort caused by the cold treatment is limited. The cold slurry is sterile and biocompatible; and, as such, the cold slurry 125 can be advantageously left in the body (e.g. no removal of the slurry is necessary after cooling has been effected).



FIG. 2 shows an example of the generating end 115 for making cold slurry from mixing liquid water and solid water. The application cannula 105 houses a first delivery cannula 205 for supplying liquid water 210 (or a liquid mix of water and glycerol) and a second delivery cannula 215 for supplying solid water (ice) 220. The distal end of the first delivery cannula 205 is open and forms a first outlet 230 for the liquid water 210 to exit. The distal end of the second delivery cannula 215 is open and forms a second outlet 235 for the solid water 220 to exit. The outlets 230, 235 are arranged so that the liquid water 210 and the solid water 220 mix together as they exit to form a cold slurry.



FIG. 3A shows an example of the generating end 115 for making cold slurry from mixing liquid water and solid water. This example is similar to the one described above with reference to FIG. 2 with the addition of a grinder 240 located in front of the second outlet 235. The arrangement of the grinder 240 with respect to the second outlet 235 is better seen in the cross-sectional view of FIG. 3B. As the solid water 220 emerges from the second delivery cannula 215, the grinder 240 breaks the solid water 220 into particles 245. The liquid water 210 exiting from the first delivery cannula 205 mixes with the particles 245 to form a cold slurry. In another example (not shown), a vibrator can break solid water into particles to make cold slurry at the point of delivery.



FIG. 4 shows another example of the generating end 115 for making a cold slurry from mixing liquid water and solid water. The application cannula 105 houses a first delivery cannula 305 for providing a first supply of liquid water 310 (or mix of water and glycerol) and a second delivery cannula 315 for providing a second supply of liquid water 320. As shown, the application cannula 105 further includes a gas line 325 for spraying a cooling gas 330 and freezing the second supply of water 320 into solid water 335.


The distal end of the first delivery cannula 305 is open forming a first outlet 340 for the first supply of liquid water 310 to exit. The distal end of the second delivery cannula 315 is open forming a second outlet 345 for the solid water 335 to exit. In front of the second outlet 345, there is a grinder (or vibrator) 350 to break the solid water 335 into particles as it emerges from the second delivery cannula 315. The outlets 340, 345 are arranged so that the first supply of liquid water 310 and the particles of solid water mix together to form a cold slurry.



FIG. 5 shows an example of the generating end 115 for making cold slurry from crystalizing supercooled water. The application cannula 105 houses a first delivery cannula 405 for supplying supercooled water 410. Water normally freezes at 273.15 K (0° C. or 32° F.), but it can be “supercooled” at standard pressure down to its crystal homogeneous nucleation at almost 224.8 K (−48.3° C./−55° F.). The supercooling process requires that water be pure and free of nucleation sites. This can be done by processes like reverse osmosis or chemical demineralization. Rapidly cooling water at a rate on the order of 10^6 K/s avoids crystal nucleation and water becomes a glass, i.e., an amorphous (non-crystalline) solid.


The application cannula 105 further houses a second delivery cannula 415 for supplying ice pellets 420, which serves as nucleation sites for the crystallization process. The distal end of the first delivery cannula 405 is open and forms a first outlet 430 for the supercooled water 410 to exit. The distal end of the second delivery cannula 415 is open and forms a second outlet 435 for the ice pellets 420 to exit. The outlets 430, 435 are arranged so that the supercooled water 410 interacts with the ice pellets 420 causing it to crystalize and form a cold slurry.



FIG. 6A shows another example of the point of delivery generation device. The device includes an application cannula 605 that is open at its distal end defining an outlet 610. A generating end 615 includes an outer balloon 620 disposed around the outlet 610. The application cannula 605 is in fluid communication with the interior volume of the outer balloon 620. The application cannula 605 includes a fluid delivery cannula 625. The application cannula 605 and the fluid delivery cannula 625 share a common longitudinal axis and can be said to be coaxial aligned.


The fluid delivery cannula 625 is open at its distal end defining a fluid outlet 630. The generating end 615 further includes an inner balloon 635 disposed around the fluid outlet 630. The fluid delivery cannula 625 is in fluid communication with an interior volume of the inner balloon 635, which is labeled 640 in the figure. The inner balloon 635 is located inside the outer balloon 620. As shown, the inner balloon 635 occupies a portion of the interior volume of the outer balloon 620 leaving a space or gap 645 between an outer wall of the inner balloon 635 (which is labeled 650 in the figure) and an inner wall of the outer balloon 620 (which is labeled 655 in the figure).


To generate a cold slurry at the point of delivery, the application cannula 605 is inserted through a patient's skin and the generating end 615 is advanced to a location at or near a target tissue in much the same manner as described above with reference to FIG. 1. In this example, the outer balloon 620 and the inner balloon 635 are inserted into the patient's body in their uninflated state. The inner balloon 635 is then filled or inflated with a cool fluid, such as mix of cold water and cold glycerol that is supplied through the fluid delivery cannula 625.


Once the inner balloon 635 is filled with the cool fluid, the outer balloon 620 is filled with a cooling gas or fluid, such as liquid nitrogen. The cooling gas fills the gap 645 between the inner balloon 635 and the outer balloon 620. This causes the cool fluid in the inner balloon 635 to partial freeze and form a cold slurry 660, as shown in FIG. 6B. (For clarity the outer balloon 620 is not shown in FIG. 6B.) The slurry-filled inner balloon 635 can then be used to cool a target tissue. Alternatively, the inner balloon 635 can be ruptured by a retractable puncture needle 665 that extends beyond the application cannula 605 when extended as shown. Rupturing the inner balloon 635 releases the cold slurry 600 at or near the target tissue.



FIG. 7 shows another example of the point of delivery generation delivery device for generating and replenishing cold slurry. This example is similar to the one described above with reference to FIG. 6 with the addition of a fluid return cannula 670. (For clarity the outer balloon 620 is not shown in FIG. 7.) The fluid return cannula 670 is housed within the application cannula 605 together with the fluid delivery cannula 625, as shown. The fluid return cannula 670 removes cold slurry from the inner balloon 635 that is no longer at the desired temperature. Replenishing the “old” cold slurry with “fresh” cold slurry in this manner can accommodate for the eventually melting of cold slurry. This approach is particular useful for a treatment that requires a long period of cooling.



FIG. 8 shows an example point of delivery generation device having multiple cannulas or “working channels” to control the functions described above with reference to FIGS. 6A, 6B, and 7. The device includes an application cannula 705. The application cannula 705 houses a gas delivery cannula 710, a fluid delivery cannula 715, and a fluid return cannula 720, to continuously generate and replenish cold slurry, as described above with reference to FIGS. 6A and 7. The application cannula 705 can also include a retractable puncture needle 725 to rupture a balloon filled with cold slurry, as described above with reference to FIG. 6B. The application cannula 705 can further have a cold slurry temperature monitor 730 for measuring the temperature of the cold slurry.

Claims
  • 1. A method of making a cold slurry at or near a target tissue underneath a subject's skin, the method comprising: delivering a first component to a target tissue underneath a subject's skin;delivering a second component to the target tissue; andforming a cold slurry at or near the target tissue from an interaction between the first component and the second component.
  • 2. The method of claim 1, wherein the steps of delivering and the step of forming the cold slurry are carried out continuously.
  • 3. The method of claim 1, wherein the first component is a liquid water and the second component is solid water.
  • 4. The method of claim 3 further comprising breaking the solid water into particles of solid water at or near the target tissue.
  • 5. The method of claim 3 further comprising forming the solid water by freezing liquid water at or near the target tissue.
  • 6. The method of claim 1, wherein the first component is supercooled water and the second component is pellets of solid water; and wherein the interaction is crystal nucleation of the supercooled water caused by the pellets of solid water.
  • 7. The method of claim 1, wherein the first component is liquid water contained in an inner balloon and the second component is a cooling fluid surrounding the inner balloon and contained within an outer balloon; and wherein the interaction is heat transferring from the liquid water to the cooling fluid.
  • 8. The method of claim 7 further comprising puncturing the inner and outer balloons to release the cold slurry at or near the target tissue.
  • 9. A device for making a cold slurry at or near a target tissue underneath a subject's skin, the device comprising: a first cannula for delivering a first component to a target tissue underneath a subject's skin, the first cannula comprising a first open distal end and first longitudinal axis extending from the first open distal end;a second cannula for delivering a second component to the target tissue, the second cannula comprising a second open distal end and a second longitudinal axis extending from the second open distal end, the second longitudinal axis aligned with the first longitudinal axis;wherein the first open distal end is proximate to the second open distal end for forming a cold slurry at or near the target tissue from an interaction between the first component and the second component.
  • 10. The device of claim 9, wherein the first component is liquid water and the second component is solid water.
  • 11. The device of claim 10 further comprising a grinder disposed about the second open distal end to break the solid water into particles of solid water at or near the target tissue.
  • 12. The device of claim 10 further comprising a vibrator disposed about the second open distal end to break the solid water into particles of solid water at or near the target tissue.
  • 13. The device of claim 10 further comprising a third cannula extending along the second cannula for carrying a cooling gas to form the solid water from liquid water at or near the target tissue.
  • 14. The device of claim 9, wherein the first component is supercooled water and the second component is pellets of solid water; and wherein the interaction is crystal nucleation of the supercooled water caused by the pellets of solid water.
  • 15. The device of claim 9 further comprising: an inner balloon disposed around the first open distal end of the first cannula, the inner balloon comprising an outer surface and a volume in fluid communication with the first cannula to receive the first component;an outer balloon disposed around the second open distal end of the second cannula, the outer balloon comprising an inner surface and a volume in fluid communication with the second cannula to receive the second component; andwherein the outer surface of the inner balloon and the inner surface of the outer balloon form a space for the interaction between the first and second components to occur, and form the cold slurry inside the inner balloon.
  • 16. The device of claim 15, wherein the first component is a mixture of water and glycerol; and wherein the second component is a cooling gas.
  • 17. The device of claim 15 further comprising a puncture needle extending along the second cannula and movable between an extended position and a retracted position; and wherein the puncture needle in the extended position breaks the inner balloon and the outer balloon, and releases the cold slurry at or near the target tissue.
  • 18. The device of claim 9 further comprising a temperature sensor extending beyond the first and second open distal ends to measure the temperature of the cold slurry made at or near the target tissue.
  • 19. The device of claim 9, wherein the first and second cannulas each have a size and shape suitable for inserting through the subject's skin.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application Ser. No. 62/482,003 filed on Apr. 5, 2017, the entire disclosure of which is incorporated herein by reference.

US Referenced Citations (209)
Number Name Date Kind
3373906 Hart et al. Mar 1968 A
3893834 Armstrong Jul 1975 A
4619678 Rubin Oct 1986 A
4966601 Draenert Oct 1990 A
4983045 Taniguchi Jan 1991 A
4986079 Koseki et al. Jan 1991 A
5143063 Fellner Sep 1992 A
5304128 Haber et al. Apr 1994 A
5445523 Fischer et al. Aug 1995 A
5507790 Weiss Apr 1996 A
5769879 Richards et al. Jun 1998 A
6032675 Rubinsky Mar 2000 A
6041787 Rubinsky Mar 2000 A
6067803 Wolsey et al. May 2000 A
6244052 Kasza Jun 2001 B1
6300130 Toner et al. Oct 2001 B1
6324863 Henry Dec 2001 B1
6334328 Brill Jan 2002 B1
6403376 Toner et al. Jun 2002 B1
6413444 Kasza Jul 2002 B1
6428563 Keller Aug 2002 B1
6430957 Inada et al. Aug 2002 B1
6458109 Henley et al. Oct 2002 B1
6475212 Dobak, III et al. Nov 2002 B2
6547811 Becker et al. Apr 2003 B1
6575930 Trombley, III et al. Jun 2003 B1
6673607 Toner et al. Jan 2004 B2
6849072 Lee et al. Feb 2005 B2
6962601 Becker et al. Nov 2005 B2
7118591 Frank et al. Oct 2006 B2
7276051 Henley et al. Oct 2007 B1
7367341 Anderson et al. May 2008 B2
7389653 Kasza et al. Jun 2008 B2
7422601 Becker et al. Sep 2008 B2
7507234 Utley et al. Mar 2009 B2
7588547 Deem et al. Sep 2009 B2
7603868 Sveinsson Oct 2009 B2
7681411 DiLorenzo Mar 2010 B2
7713266 Elkins et al. May 2010 B2
7854754 Ting et al. Dec 2010 B2
8117854 Lampe et al. Feb 2012 B2
8192474 Levinson Jun 2012 B2
8275442 Allison Sep 2012 B2
8285390 Levinson et al. Oct 2012 B2
8298216 Burger et al. Oct 2012 B2
8308681 Slocum et al. Nov 2012 B2
8337539 Ting et al. Dec 2012 B2
8505315 Kasza et al. Aug 2013 B2
8523927 Levinson et al. Sep 2013 B2
8535275 Salzman Sep 2013 B2
8603073 Allison Dec 2013 B2
8608696 DiMeo et al. Dec 2013 B1
8676338 Levinson Mar 2014 B2
8702774 Baker et al. Apr 2014 B2
8808241 DiMeo et al. Aug 2014 B2
8840608 Anderson et al. Sep 2014 B2
8974451 Smith Mar 2015 B2
9044212 LePivert Jun 2015 B2
9078634 Gonzales et al. Jul 2015 B2
9132031 Levinson et al. Sep 2015 B2
9314368 Allison et al. Apr 2016 B2
9345526 Elkins et al. May 2016 B2
9375345 Levinson et al. Jun 2016 B2
9398930 Leung et al. Jul 2016 B2
9408745 Levinson et al. Aug 2016 B2
9522031 Anderson et al. Dec 2016 B2
9545523 Nanda Jan 2017 B2
9585687 Tenenbaum et al. Mar 2017 B2
9649220 Anderson et al. May 2017 B2
9655770 Levinson et al. May 2017 B2
9656056 Boyden et al. May 2017 B2
9980765 Avram et al. May 2018 B2
10174985 Arnitz et al. Jan 2019 B2
10406021 Wu et al. Sep 2019 B2
10500342 Velis Dec 2019 B2
20010005338 Muhlbauer et al. Jun 2001 A1
20020107199 Walker Aug 2002 A1
20030012079 Coffeen et al. Jan 2003 A1
20030032996 Hallman Feb 2003 A1
20030074903 Upadhye et al. Apr 2003 A1
20030171715 Hommann et al. Sep 2003 A1
20030220674 Anderson et al. Nov 2003 A1
20040073280 Dae et al. Apr 2004 A1
20040092883 Casey et al. May 2004 A1
20040092920 Rozenshpeer May 2004 A1
20040199115 Rosenman Oct 2004 A1
20040220559 Kramer et al. Nov 2004 A1
20050203598 Becker et al. Sep 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20060030843 Lane et al. Feb 2006 A1
20060036302 Kasza et al. Feb 2006 A1
20060122673 Callister et al. Jun 2006 A1
20060161232 Kasza et al. Jul 2006 A1
20060190066 Worthen Aug 2006 A1
20070010861 Anderson et al. Jan 2007 A1
20070056313 Kasza et al. Mar 2007 A1
20070106247 Burnett et al. May 2007 A1
20070198071 Ting et al. Aug 2007 A1
20070255362 Levinson et al. Nov 2007 A1
20070270925 Levinson Nov 2007 A1
20080045880 Kjeken et al. Feb 2008 A1
20080077201 Levinson et al. Mar 2008 A1
20080077202 Levinson Mar 2008 A1
20080077211 Levinson et al. Mar 2008 A1
20080161772 Nayak et al. Jul 2008 A1
20080195114 Murphy Aug 2008 A1
20080236186 Kasza et al. Oct 2008 A1
20080287839 Rosen et al. Nov 2008 A1
20080300540 Lewis Dec 2008 A1
20090012497 Uber, III et al. Jan 2009 A1
20090018623 Levinson et al. Jan 2009 A1
20090018624 Levinson et al. Jan 2009 A1
20090018625 Levinson et al. Jan 2009 A1
20090018626 Levinson et al. Jan 2009 A1
20090018627 Levinson et al. Jan 2009 A1
20090030366 Hoch Jan 2009 A1
20090071829 O'Banion et al. Mar 2009 A1
20090118722 Ebbers et al. May 2009 A1
20090125087 Becker et al. May 2009 A1
20090149929 Levinson et al. Jun 2009 A1
20090255276 Kasza et al. Oct 2009 A1
20090270814 Masi et al. Oct 2009 A1
20100036295 Altshuler et al. Feb 2010 A1
20100081971 Allison Apr 2010 A1
20100152824 Allison Jun 2010 A1
20100152880 Boyden et al. Jun 2010 A1
20100249753 Gaisser et al. Sep 2010 A1
20100274184 Chun Oct 2010 A1
20100280582 Baker et al. Nov 2010 A1
20100308257 Lampe et al. Dec 2010 A1
20100312202 Henley et al. Dec 2010 A1
20110066216 Ting et al. Mar 2011 A1
20110190751 Ingle et al. Aug 2011 A1
20110238050 Allison et al. Sep 2011 A1
20110238051 Levinson et al. Sep 2011 A1
20110300079 Martens et al. Dec 2011 A1
20120000217 Gudnason Jan 2012 A1
20120022518 Levinson Jan 2012 A1
20120055187 Raines et al. Mar 2012 A1
20120167878 Belzon et al. Jul 2012 A1
20120203312 Batzer et al. Aug 2012 A1
20120239123 Weber et al. Sep 2012 A1
20120289761 Boyden et al. Nov 2012 A1
20130066309 Levinson Mar 2013 A1
20130079684 Rosen et al. Mar 2013 A1
20130116758 Levinson et al. May 2013 A1
20130116759 Levinson et al. May 2013 A1
20130158440 Allison Jun 2013 A1
20130158636 Ting et al. Jun 2013 A1
20130190744 Avram et al. Jul 2013 A1
20130245731 Allison Sep 2013 A1
20130253496 Anderson et al. Sep 2013 A1
20130319080 Sezaki et al. Dec 2013 A1
20140005760 Levinson et al. Jan 2014 A1
20140067025 Levinson et al. Mar 2014 A1
20140091113 Brewster et al. Apr 2014 A1
20140200511 Boyden et al. Jul 2014 A1
20140257443 Baker et al. Sep 2014 A1
20140277219 Nanda Sep 2014 A1
20140277302 Weber et al. Sep 2014 A1
20140303608 Taghizadeh Oct 2014 A1
20140303696 Anderson et al. Oct 2014 A1
20140303697 Anderson et al. Oct 2014 A1
20140316393 Levinson Oct 2014 A1
20140358079 Fischell et al. Dec 2014 A1
20140378937 Anderson et al. Dec 2014 A1
20150090769 Lotsch Mar 2015 A1
20150112195 Berger et al. Apr 2015 A1
20150141916 Albrecht et al. May 2015 A1
20150216816 O'Neil et al. Aug 2015 A1
20150297246 Patel et al. Oct 2015 A1
20150320938 King et al. Nov 2015 A1
20150328077 Levinson Nov 2015 A1
20150342780 Levinson et al. Dec 2015 A1
20150343156 Fischell et al. Dec 2015 A1
20160051401 Yee et al. Feb 2016 A1
20160058956 Cohn et al. Mar 2016 A1
20160081974 Lee et al. Mar 2016 A1
20160089550 DeBenedictis et al. Mar 2016 A1
20160112195 Jochheim et al. Apr 2016 A1
20160128767 Azamian et al. May 2016 A1
20160175141 Wu et al. Jun 2016 A1
20160184568 Harris et al. Jun 2016 A1
20160242661 Fischell et al. Aug 2016 A1
20160317621 Bright Nov 2016 A1
20160354137 Fischell et al. Dec 2016 A1
20160354237 Gonzales et al. Dec 2016 A1
20170035603 Kammer et al. Feb 2017 A1
20170051353 Eng Feb 2017 A1
20170105869 Frangineas, Jr. Apr 2017 A1
20170136237 Eckhouse et al. May 2017 A1
20170143538 Lee et al. May 2017 A1
20170164965 Chang et al. Jun 2017 A1
20170202613 Pellegrino et al. Jul 2017 A1
20170246032 Gonzales et al. Aug 2017 A1
20170274011 Garibyan et al. Sep 2017 A1
20170274078 Garibyan et al. Sep 2017 A1
20170325992 DeBenedictis et al. Nov 2017 A1
20180008500 Anderson et al. Jan 2018 A1
20180116868 Velis et al. May 2018 A1
20180140514 Velis et al. May 2018 A1
20180289538 Velis Oct 2018 A1
20180311079 Garibyan et al. Nov 2018 A1
20190053939 Garibyan et al. Feb 2019 A1
20190054242 Velis Feb 2019 A1
20200046552 Velis et al. Feb 2020 A1
20200086054 Velis Mar 2020 A1
20200113627 Alas et al. Apr 2020 A1
20200114041 Alas et al. Apr 2020 A1
Foreign Referenced Citations (24)
Number Date Country
102271741 Dec 2011 CN
102307545 Jan 2012 CN
103110473 May 2013 CN
104010598 Aug 2014 CN
105640706 Jun 2016 CN
0418979 Mar 1991 EP
0 445 951 Sep 1991 EP
2 421 545 Sep 2013 ES
2 338 428 Dec 1999 GB
2003-500097 Jan 2003 JP
2008-529663 Aug 2008 JP
2009-539575 Nov 2009 JP
2006086479 Aug 2006 WO
2009086399 Jul 2009 WO
2009089090 Jul 2009 WO
2013036540 Mar 2013 WO
2013113970 Aug 2013 WO
2016033380 Mar 2016 WO
2016033384 Mar 2016 WO
2016054165 Apr 2016 WO
2016090175 Jun 2016 WO
2016138045 Sep 2016 WO
2017196548 Nov 2017 WO
2018187573 Oct 2018 WO
Non-Patent Literature Citations (35)
Entry
Ash, 2003, Chronic peritoneal dialysis catheters: overview of design, placement, and removal procedures, Int Nephrol Dialysis 16(4):323-34.
Brink, 2008, Abdominoplasty with direct resection of deep fat, Plast Reconstructive Surg 123(5):1597-1603.
Ding, 2008, The association between non-subcutaneous adiposity and calcified coronary plaque: A substudy of the multi-ethnic study of atherosclerosis, Am J Clin Nutr 88(3):645-650.
Fox, 2007, Abdominal visceral and subcutaneous adipose tissue compartments—association with metabolic risk factors in the Framingham heart study, Circulation 116:39-48.
Garaulet, 2006, Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans, Int J Obes 30(6):899-905.
Gradinger, 2005, Abdominoplasty, Chapter 83, pp. 2935-3026, in The art of aesthetic surgery: principles & techniques, Nahai, Ed., Quality Med Pub, St. Louis Mo. (92 pages).
International Search Report & Written Opinion dated Aug. 29, 2018 for PCT/US2018/026273 (15 pages).
International Search Report and Written Opinion dated Apr. 12, 2011, for PCT/US11/24766, filed Feb. 14, 2011 (11 pages).
International Search Report and Written Opinion dated May 7, 2018, for PCT/US18/20387, filed Mar. 1, 2018 (7 pages).
International Search Report and Written Opinion dated Jun. 11, 2018, for PCT/US2018/026260, filed Apr. 5, 2018 (6 pages).
Laven, 2006, A pilot study of ice-slurry application for inducing laparoscopic renal hypothermia, BJU Int 99:166-70.
Laverson, 2006, Improving abdominoplasty results: reconstruction of the linea alba sulcus by direct excision, Aesthetic Surg J 26:682-6.
Stevens, 2014, Does cryolipolysis lead to skin tightening? A first report of cryodermadstringo, Aesth Surg J 34(6):NP32-NP34.
Yamamoto, 2010, Adipose depots possess unique developmental gene signatures, Obesity 18(5):872-78.
Extended European Search Report dated Dec. 9, 2020 in European Application No. 18781693.9.
Search Report and Written Opinion dated Feb. 17, 2021 in Singapore Application No. 11201909303T, with English translation.
Search Report and Written Opinion dated Feb. 8, 2021 in Singapore Application No. 11201909305P, with English translation.
International Search Report and Written Opinion dated May 7, 2018, for PCT/US2018/20387, filed Mar. 1, 2018 (7 pages).
Int Search Report & Written Op dated June 11, 2018, for PCT/US2018/026260, filed April 5, 2018 (6 pages)
Esposito, 2016, Do you know this syndrome? Type 2 benign symmetric lipomatosis (Launois-Bensaude), Brazilian Annals of Dermatology 91:841.
Gentile, 2016, Lipodystrophy in Insulin-Treated Subjects and other Injection-Site Skin Reactions: Are we Sure Everything is Clear?, Diabetes Therapy 7.
International Preliminary Report on Patentability dated Aug. 21, 2012, for International application No. PCT/US2011/024766, filed Feb. 14, 2011 (8 pages).
Int Search Report & Written Op dated Dec. 11, 2019, for PCT/US2019/054828, filed Oct. 4, 2019 (8 pages).
Int Search Report & Written Op dated Dec. 23, 2019, for PCT/US2019/054834, filed Oct. 4, 2019 (10 pages).
Int Search Report & Written Op dated Feb. 11, 2020, for PCT/US2019/055633, filed Oct. 10, 2019 (12 pages).
Int Search Report & Written Op dated Jan. 2, 2020, for PCT/US2019/055605, filed Oct. 10, 2019 (9 pages).
International Search Report and Written Opinion dated May 15, 2018, for PCT/US2017/059947, filed Nov. 3, 2017 (8 pages).
Kanamori, 2015, “A case of an 8-year-old boy who was strongly suspected of suffering from familial angiolipomatosis”, J Pediatric Surg 3.
Kosseifi, 2010, “Dercum's Disease: An Unusual Presentation”, Pain Medicine 11:1432.
Lv, 2017, “A review of the postoperative lymphatic leakage”, Oncotarget 8:69069.
Popescu, 2014, “Proteus Syndrome: a difficult diagnosis and management plan”, J Med and Life 7:1.
Extended European Search Report dated Dec. 16, 2020 in European Application No. 18781069.2.
Extended European Search Report dated Aug. 28, 2020 in European Application No. 17868153.2.
Written Opinion dated Jul. 1, 2020 in Singapore Application No. 11201903946S.
Office Action dated Mar. 1, 2021 in Chinese Application No. 2017800786800, with English translation.
Related Publications (1)
Number Date Country
20180289537 A1 Oct 2018 US
Provisional Applications (1)
Number Date Country
62482003 Apr 2017 US